Trial Profile
A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Adenocarcinoma; Liver cancer; Lung cancer; Pancreatic cancer; Peritoneal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2024 Results for four year survival update, presented at the 2024 Gastrointestinal Cancers Symposium
- 27 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 24 Jul 2023 Results (n=42) assessing Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib published in the Clinical Cancer Research